The question is not whether fertility care will grow. It is which way five competing forces net out for your business, and whether you can see it before your financials do.
Consolidation, expanded coverage, a fragmenting benefits layer, a public drug price reset, and new gonadotropin competition are arriving together. Clinic networks, pharmacies, and manufacturers will not feel them the same way.
Clinic networks keep acquiring the few top-tier independent practices that remain. US Fertility recently acquired PREG, a large Southeast group that networks had pursued for years, and RMA bought Illume’s five offices in New York and Connecticut. Each acquisition adds another set of physicians, protocols, and systems to integrate.
Fertility pharmacies are consolidating too, and the ones that survive tend to win on service rather than price alone. Mandell’s, for example, has built its position on taking administrative work off clinic nurses. Generic and biosimilar manufacturers such as Meitheal are adding competition in the medications themselves.
In May 2026, the Departments of Labor, Health and Human Services, and Treasury proposed a rule that would let employers offer fertility benefits as a new category of limited excepted benefits, the same category as dental and vision. The Departments estimate that nearly a million participants would enroll.
If finalized, more employers, particularly mid-market ones, will be able to offer fertility coverage, and more patients will arrive insured rather than paying cash. The rule is not final, and its terms and timing may change.
Much of the new coverage will flow through fertility benefits managers, and they do not all pay the same way.
Progyny bundles treatment into full-cycle coverage with its own clinic network and pharmacy. The manager controls the protocol, the network, and often the drug channel.
Carrot gives members a fixed lifetime fund to spend, which likely makes patients more sensitive to drug and treatment prices.
Maven folds fertility into a broader family-health platform connected to hundreds of clinics.
Kindbody owns clinics and labs, making it both a channel and a competitor. Insurers are also pushing to carry fertility back inside the medical plan.
In late 2025, EMD Serono agreed to offer its three main IVF medications to cash-pay patients through TrumpRx at an 84 percent discount from list price, starting in January 2026, and large pharmacy operators joined the program.
Beyond the discount itself, the deal created a public reference price that every pharmacy, benefits manager, and employer can now compare against.
Human menopausal gonadotropin (hMG), a staple of IVF stimulation protocols, has been dominated in the U.S. by Ferring’s Menopur. That may change. EMD Serono is seeking U.S. approval for Pergoveris, which is used in similar protocols. Granata Bio’s GB-hMG is in a pivotal Phase III study, GRACE, that the company expects to support a Biologics License Application. Meitheal, meanwhile, has already brought generic fertility medications such as GnRH antagonists to market.
Clinics stand to gain covered patients and cheaper cycles, but much of that volume will arrive through benefits managers that negotiate rates and steer patients. Pharmacies stand to gain from more cycles, but each fill may be worth less as drug prices fall, and some of the new demand may flow through benefits-manager networks or direct-to-consumer programs instead. These forces pull in different directions, and the balance between them will keep shifting as they take shape.
What matters for any single business is knowing where it sits and how each force is affecting it as conditions evolve. That understanding is important today, and it will matter more as these forces mature.
Which managers its patients come through, which drugs and contracts it depends on, and how much of its volume is cash-pay all shape the result. Two pharmacies of the same size can end up in very different places.
These forces interact. A drop in pharmacy margin might come from a lower cash reference price, a shift in benefits-manager mix, a rebate threshold missed after a new product launch, or patients moving to another channel, and each calls for a different response.
Most fertility businesses cannot see these signals today, and not for lack of reporting tools. The patient journey runs through clinic EMRs and patient-engagement software, while dispensing, acquisition cost, and rebate data sit in separate pharmacy systems, and each acquired practice brings its own definitions.
A semantic layer and a shared model of the business, so a cycle, a patient, and a margin mean the same thing everywhere.
Drivers of patient attrition, forecasts of crossing or missing rebate thresholds, and separating price effects from mix shifts.
An independent read on whether new AI tools for stimulation, embryo selection, and prognosis improve outcomes or throughput.
A dashboard is only the last step, where that work becomes visible. We have done this kind of work before, including reducing costs by about 40 percent in a core part of a PE-backed fertility pharmacy’s business and lifting retention by 10 percent within a month.
The same foundation also changes who can do the analysis. With clear data governance in place, defining who owns each data domain, who stewards its definitions and quality, and who maintains the systems as custodian, clinic and pharmacy leaders no longer have to queue every question behind IT. A well-built semantic layer, AI tools that work against it, and the right training let operations, revenue cycle, and finance teams build the analytics they need themselves, while IT concentrates on keeping systems reliable and available. When policy and pricing are moving this quickly, the teams closest to the business need to be able to ask new questions as the forces shift, not wait for the next reporting cycle.
The businesses that come through this repricing best will not be the ones that guessed right about policy. They will be the ones that could see, in their own data, which forces were moving them, and acted first.
A short conversation is enough to see where your data can already answer these questions, and where the foundation needs work.
A read on how these forces net out for a portfolio company, and what belongs in the value creation plan.
Compare NotesA governed data foundation and economic models that show what moved your margins and why.
Map the Forces